ethyl 1-(4-nitrophenyl)piperidine-3-carboxylate | 911105-84-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: ethyl 1-(4-nitrophenyl)piperidine-3-carboxylate
• CAS: 911105-84-5
• 化学式: C₁₄H₁₈N₂O₄
• 分子量: 278.308
• InChiKey: XURKQOWHSLGEGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.37
• 重原子数：
  20.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  72.68
• 氢给体数：
  0.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  ethyl 1-(4-nitrophenyl)piperidine-3-carboxylate 在 4-二甲氨基吡啶 、 palladium 10% on activated carbon 、 氢气 、 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 20.0~60.0 ℃ 、101.33 kPa 条件下， 反应 30.0h， 生成 ethyl 1-(4-((S)-5-((1,3-dioxoisoindolin-2-yl)methyl)-2-oxooxazolidin-3-yl)phenyl)piperidine-3-carboxylate
  参考文献：
  名称：

  Transformation of a selective factor Xa inhibitor rivaroxaban into a dual factor Xa/thrombin inhibitor by modification of the morpholin-3-one moiety

  摘要：

  将选择性因子Xa抑制剂利伐沙班中的P4吗啉-3-酮部分替换为2-乙氧基羰基哌啶，得到了一种双重因子Xa/凝血酶抑制剂24，其对因子Xa的Ki值为62 ± 18 nM，对凝血酶的Ki值为353 ± 75 nM。提出的双重活性合理化为“设计”凝血酶抑制活性到强效因子Xa抑制剂利伐沙班提供了良好的起点。

  DOI：

  10.1039/c3md00250k
• 作为产物：
  描述：

  对氟硝基苯 、 3-哌啶甲酸乙酯 在 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 15.0h， 以93%的产率得到ethyl 1-(4-nitrophenyl)piperidine-3-carboxylate
  参考文献：
  名称：

  Transformation of a selective factor Xa inhibitor rivaroxaban into a dual factor Xa/thrombin inhibitor by modification of the morpholin-3-one moiety

  摘要：

  将选择性因子Xa抑制剂利伐沙班中的P4吗啉-3-酮部分替换为2-乙氧基羰基哌啶，得到了一种双重因子Xa/凝血酶抑制剂24，其对因子Xa的Ki值为62 ± 18 nM，对凝血酶的Ki值为353 ± 75 nM。提出的双重活性合理化为“设计”凝血酶抑制活性到强效因子Xa抑制剂利伐沙班提供了良好的起点。

  DOI：

  10.1039/c3md00250k

文献信息

• Syk inhibitor and use method therefor
  申请人：CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

  公开号：US11091460B2

  公开（公告）日：2021-08-17

  Provided are a Syk inhibitor and a use method therefor, and in particular, disclosed are quinolinone represented by formula (I) or quinazoline derivatives or pharmaceutically acceptable salts thereof, a preparation method, a pharmaceutical composition, and uses in preparing a medicament for treatment of Syk receptor related diseases.

  本发明提供了一种Syk抑制剂及其使用方法，特别是公开了式(I)代表的喹啉酮或喹唑啉衍生物或其药学上可接受的盐、制备方法、药物组合物以及制备治疗Syk受体相关疾病的药物的用途。
• SYK INHIBITOR AND USE METHOD THEREFOR
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：EP3640247B1

  公开（公告）日：2022-01-12
• Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores
  作者：Uroš Trstenjak、Janez Ilaš、Danijel Kikelj

  DOI：10.1016/j.ejmech.2013.03.056

  日期：2013.6

  Dual antithrombotic agents acting as anticoagulants and aggregation inhibitors could have substantial advantages over currently prescribed combinations of antithrombotic drugs. Herein, we report compounds with moderate inhibitory activity for factor Xa and fibrinogen GPIIb/IIIa binding (both in the micromolar range). These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor rivaroxaban with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity. Resulting from this study, a structurally novel class of submicromolar fibrinogen GPIIb/IIIa binding inhibitor bearing 1,2,4-oxadiazol-5(4H)-one moiety is also described. (C) 2013 Elsevier Masson SAS. All rights reserved.
• Transformation of a selective factor Xa inhibitor rivaroxaban into a dual factor Xa/thrombin inhibitor by modification of the morpholin-3-one moiety
  作者：Uroš Trstenjak、Janez Ilaš、Danijel Kikelj

  DOI：10.1039/c3md00250k

  日期：——

  Replacement of the P4 morpholin-3-one moiety in a selective factor Xa inhibitor rivaroxaban by 2-ethoxycarbonylpiperidine resulted in a dual factor Xa/thrombin inhibitor 24, possessing a Ki of 62 ± 18 nM for factor Xa and a Ki of 353 ± 75 nM for thrombin. Presented rationalization of dual activity provides a good starting point for “designing in” thrombin inhibitory activity to potent factor Xa inhibitor rivaroxaban.

  将选择性因子Xa抑制剂利伐沙班中的P4吗啉-3-酮部分替换为2-乙氧基羰基哌啶，得到了一种双重因子Xa/凝血酶抑制剂24，其对因子Xa的Ki值为62 ± 18 nM，对凝血酶的Ki值为353 ± 75 nM。提出的双重活性合理化为“设计”凝血酶抑制活性到强效因子Xa抑制剂利伐沙班提供了良好的起点。